Investor Relations Home
Rigel currently has the following product candidates in development: fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, which is in Phase 3 clinical trials for ITP and initiating a Phase 2 clinical trial for IgA nephropathy (IgAN); R348, a topical JAK/SYK inhibitor, in a Phase 2 clinical trial for dry eye in ocular graft-versus-host disease (GvHD); two oncology product candidates in Phase 1 development with partners BerGenBio AG and Daiichi; and two preclinical programs with partners AstraZeneca for R256 in asthma and Bristol-Myers Squibb for TGF beta inhibitors in immuno-oncology.
Rigel Pharmaceuticals Inc. at Jefferies 2015 Healthcare Conference Presentation (Live)
June 3, 2015 at 1:30 p.m. ET
|05/07/15||Rigel Announces First Quarter 2015 Financial Results|
|- Conference Call and Webcast Today at 4:30 PM Eastern Time -
SOUTH SAN FRANCISCO, Calif., May 7, 2015 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the first quarter ended March 31, 2015.
For the first quarter of 2015, Rigel reported a net loss of $18.2 million, or $0.21 per share, compared to a net loss of $22.3 million, or $0.25 per share, in the first quarter of 2014. Weighted average shares outstanding for the first quarters of 2015 a... |
|04/30/15||Rigel Announces Conference Call and Webcast to Report First Quarter 2015 Financial Results and Pipeline Update|
|SOUTH SAN FRANCISCO, Calif., April 30, 2015 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its first quarter 2015 financial results after market close on Thursday, May 7, 2015. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30pm Eastern Time (1:30pm Pacific Time) to discuss the financial results and provide an update on the Company's clinical programs and pipeline.
Participants can access the li... |
|* Data collected 05/12/15 - 05/19/15|
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.